Navigation Links
ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
Date:10/8/2009

MINNEAPOLIS, Oct. 8 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD and PUMDU) today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE). The results of the clinical study will be submitted to the U.S. Food and Drug Administration (FDA) in support of a 510(k) application in the near future after third party validation of the data.

In an earlier clinical study conducted by Artann Laboratories and Dr. Robert Weiss at the Robert Wood Johnson Medical Center, and published in the peer-reviewed journal Urology, 168 patients were assessed using the ProUroScan system to demonstrate the technology's ability to provide an objective and reproducible image or map of the prostate. In an ensuing meeting with the FDA, a modified clinical study was discussed which would involve imaging at least 40 patients using an enhanced version of the ProUroScan imaging system.

This study, which closed on September 25 with support from Artann Laboratories, ultimately included 57 patients recruited at the following medical centers:

  • University of Minnesota Veterans Affairs Medical Center, Minneapolis, Minn.;
  • Robert Wood Johnson Medical School Division of Urology, New Brunswick, N.J.;
  • AccuMed Research Associates, Garden City, N.Y;
  • Urological Associates of Lancaster, Lancaster, Pa.; and
  • Mayo Clinic, Rochester, Minn.

"While still preliminary, we're very encouraged by the results of our clinical study and believe they compare favorably to the March 2008 study published in Urology," said Rick Carlson, CEO of ProUroCare Medical. "The key value of this technology is the ability of the system to generate a real-time image of the prostate that physicians can use to visualize and document abnormalities in the prostate in patients identified as potentially having prostate abnormalities on digital rectal examination."

More details on the study's purpose, population, criteria and investigators is available at: http://www.clinicaltrials.gov/ct2/show/NCT00822952?term=Prostate+Mechanical+Imaging&rank=1

The ProUroScan imaging system is designed to complement the DRE, and to provide patients with potential prostate abnormalities the ability to have their prostates imaged in real time with records electronically stored for later comparison.

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is now in clinical trials for the mapping of prostate abnormalities detected by DRE. Based in Minneapolis, Minn., ProUroCare is traded on the OTCBB market.

Safe Harbor Statement

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.

SOURCE ProUroCare Medical, Inc.


'/>"/>
SOURCE ProUroCare Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare Medical Inc. Announces Pricing of Equity Offering
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology:
(Date:6/27/2017)... Simi Valley, CA (PRWEB) , ... June 27, 2017 , ... ... deployed since 2001 suffer from PTSD. Yet less than 20% will receive adequate care ... of those with PTSD won't receive any care at all. And left untreated, veterans ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center is now ... standard in tooth replacement and act as a support for prosthetic teeth, such as crowns, ... the existing bone and becomes a sturdy, lasting new root for the tooth. , ...
(Date:6/26/2017)... Lake Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... seeking 10,000 qualified mental health professionals in every state across the country to join ... an easy and rewarding way for therapists to reach a substantially greater number of ...
(Date:6/25/2017)... ... , ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from ... write in the lyrics to any song. ProLyric flies in the text for each section ... can be added modularly for optimal control. ProLyric makes editing any music video or text-based ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
Breaking Medicine News(10 mins):